Harrow, INC Form 4 insider transactions

Harrow Inc.'s Chief Scientific Officer, Amir Shojaei, was granted 30,000 stock options on January 6, 2025, which vest over four years.

John P. Saharek, CEO of ImprimisRx, a subsidiary of Harrow Inc., exercised stock options and disposed of shares to cover payroll tax liabilities and the cost to purchase the stock option.

Director Perry J. Sternberg received 8,347 Restricted Stock Units (RSUs) from Harrow, Inc. as a compensatory award, vesting quarterly over one year.

Director Martin A. Makary reports acquisition of 8,347 Restricted Stock Units (RSUs) in Harrow Inc. as a compensatory award.

Director Adrienne L. Graves reported the acquisition of 8,347 Restricted Stock Units (RSUs) of Harrow, Inc. on June 14, 2024, as a compensatory award.

Lauren P. Silvernail, a director at Harrow Inc., reported the acquisition of 8,347 Restricted Stock Units (RSUs) on June 14, 2024, as a compensatory award.

Opaleye Management Inc., a 10% owner of Harrow, Inc., reports purchasing 20,000 shares of common stock at an average price of $9.97 on April 25, 2024, increasing its indirect holdings.

Opaleye Management Inc., a 10% owner of Harrow, Inc., has increased its holdings through open market purchases of common stock on April 23 and 24, 2024.

Opaleye Management Inc., a 10% owner of Harrow, Inc., reports purchasing 29,400 shares of common stock at an average price of $10.5575 on April 19, 2024, increasing its total holdings to 3,775,000 shares.

Opaleye Management Inc., a 10% owner of Harrow, Inc., reports purchasing 50,000 shares of common stock at $12.82 per share on March 28, 2024, increasing its indirect holdings.

Harrow Inc.'s CEO, Mark L. Baum, recently acquired 9,000 shares of common stock, increasing his holdings in the company.

Opaleye Management Inc. reports purchasing 50,600 shares of Harrow, Inc. common stock at an average price of $9.65 per share, increasing its indirect holdings.

John P. Saharek, CEO of ImprimisRx (a subsidiary of Harrow, Inc.), exercised stock options to acquire 5,000 shares of common stock at $8.75 per share on March 1, 2024.